Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
1.
Experimental & Molecular Medicine ; : e181-2015.
Article Dans Anglais | WPRIM | ID: wpr-186438

Résumé

Middle East respiratory syndrome coronavirus (MERS-CoV) causes high fever, cough, acute respiratory tract infection and multiorgan dysfunction that may eventually lead to the death of the infected individuals. MERS-CoV is thought to be transmitted to humans through dromedary camels. The occurrence of the virus was first reported in the Middle East and it subsequently spread to several parts of the world. Since 2012, about 1368 infections, including ~487 deaths, have been reported worldwide. Notably, the recent human-to-human \'superspreading' of MERS-CoV in hospitals in South Korea has raised a major global health concern. The fatality rate in MERS-CoV infection is four times higher compared with that of the closely related severe acute respiratory syndrome coronavirus infection. Currently, no drug has been clinically approved to control MERS-CoV infection. In this study, we highlight the potential drug targets that can be used to develop anti-MERS-CoV therapeutics.


Sujets)
Animaux , Humains , Antiviraux/pharmacologie , Lignée cellulaire , Infections à coronavirus/traitement médicamenteux , Dipeptidyl peptidase 4/métabolisme , Épidémies de maladies , Découverte de médicament , Interactions hôte-pathogène/effets des médicaments et des substances chimiques , Coronavirus du syndrome respiratoire du Moyen-Orient/effets des médicaments et des substances chimiques , Thérapie moléculaire ciblée , Glycoprotéine de spicule des coronavirus/métabolisme
SÉLECTION CITATIONS
Détails de la recherche